A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis
Giant Cell Arteritis
In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency